常规治疗联合芪参益气滴丸治疗冠心病慢性心力衰竭的疗效观察

Observation on curative effects of conventional treatment combined with Qishen Yiqi Dropping Pill in treating chronic heart failure of coronary heart disease

关键词:  芪参益气滴丸  冠心病  心力衰竭  心功能

Key words:  Qishen Yiqi Dropping Pill  coronary heart disease  heart failure  cardiac function

摘要:

[目的] 观察芪参益气滴丸治疗冠心病慢性心力衰竭的临床疗效。[方法] 入选2017年9月—2018年12月就诊于保定市第一中心医院的冠心病慢性心力衰竭患者300例，将其按随机数字表法随机分为对照组（150例，常规治疗）和试验组（150例，常规治疗+芪参益气滴丸），观察两组患者治疗前、治疗6个月、治疗12个月后左室射血分数（LVEF）、左室舒张末内径（LVEDd）、血浆氨基末端脑钠肽前体（NT-proBNP）水平以及不良心血管事件的发生情况。[结果] 最终291例患者纳入研究，其中试验组147例，对照组144例。比较两组患者在治疗6个月、12个月时LVEF、LVEDd、NT-proBNP水平，试验组和对照组的LVEF、LVEDd、NT-proBNP均较治疗前改善，差异有统计学意义（P<0.05）；试验组的LVEF、LVEDd、NT-proBNP的改善程度均优于对照组，差异有统计学意义（P<0.05）；随访12个月后，试验组的因心血管疾病再住院率（25.9%）明显低于对照组（42.4%），差异有统计学意义（P<0.05），不良心血管事件总发生率（29.3%）显著低于对照组（47.2%），差异有统计学意义（P<0.05）。[结论] 西医常规治疗联合芪参益气滴丸可以改善冠心病慢性心力衰竭的心功能、降低患者因心血管疾病再住院率及不良心血管事件的总发生率，值得临床推广。

Abstract:

[Objective] To observe the clinical effects of QishenYiqi Dropping Pill in treating chronic heart failure of coronary heart disease.[Methods] A total of 300 patients with chronic heart failure of coronary heart disease in Baoding First Central Hospital from September 2017 to December 2018 were enrolled. The patients were randomly divided into control group (n=150,routine treatment) and experimental group (n=150,routine treatment combined with Qishen Yiqi Dripping Pills). The left ventricular ejection fraction (LVEF),left ventricular end diastolic diameter (LVEDd),N-terminal pro brain natriuretic peptide (NT-proBNP) level and the occurrence of adverse cardiovascular events were observed before treatment,6 months after treatment and 12 months after treatment.[Results] Finally,291 patients were included in the study,including 147 cases in the experimental group and 144 cases in the control group. The levels of LVEF,LVEDd and NT-proBNP in the two groups were compared at 6 months and 12 months after treatment,the LVEF,LVEDd and NT-proBNP in the experimental group and the control group were improved compared with those before treatment,and the difference was statistically significant (P<0.05). The improvement degree of LVEF,LVEDd and NT-proBNP in the experimental group was better than that in the control group (P<0.05). After 12 months' follow-up,the readmission rate of the experimental group due to cardiovascular disease (25.9%) was significantly lower than that of the control group (42.4%),with a statistically significant difference (P<0.05). And the total incidence of adverse cardiovascular events (29.3%) was significantly lower than that of the control group (47.2%),with a statistically significant difference (P<0.05).[Conclusion] Conventional Western medicine combined with Qishen Yiqi Dripping Pill can improve the heart function of patients with coronary heart disease and chronic heart failure, and reduce the rate of rehospitalization due to cardiovascular disease and the overall incidence of adverse heart failure events. It is worthy of clinical application.